Debra Yu leaving LianBio
Plus: Bayer vet Weinand appointed chair at Umoja, and updates from vTv, Gradalis, Generate and more
Debra Yu resigned as president and chief strategy officer of LianBio (NASDAQ:LIAN), effective Jan. 1, to pursue other opportunities. Yu joined the company as president and CBO in 2019 when it was first established and will stay on in a consulting capacity until June 30 to assist with the transition. Perceptive Advisors-backed LianBio is in-licensing therapies to bring them to China and other Asian markets.
Dieter Weinand became chair of Umoja Biopharma Inc. on Nov. 17. Weinand, the former CEO of Bayer Pharma AG, has held leadership roles at Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY) and Sanofi (Euronext:SAN; NASDAQ:SNY). He is also chair of Replimune Group Inc. (NASDAQ:REPL) and Mnemo Therapeutics S.A.S., and executive chair at ZielBio Inc...